Morgan Stanley has raised its price target for Cardinal Health (CAH) shares to $255 from $245, maintaining an Overweight rating. This adjustment follows the company’s strong Q2 results. Several other firms, including Baird, UBS, Evercore ISI, and Mizuho, also recently increased their price targets for Cardinal Health.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Cardinal Health price target raised to $255 from $245 at Morgan Stanley
Morgan Stanley has raised its price target for Cardinal Health (CAH) shares to $255 from $245, maintaining an Overweight rating. This adjustment follows the company’s strong Q2 results. Several other firms, including Baird, UBS, Evercore ISI, and Mizuho, also recently increased their price targets for Cardinal Health.